Investing.com -- Johnson & Johnson’s (NYSE:JNJ) medical device subsidiary Abiomed won a jury trial in Massachusetts on Thursday over allegations that it violated Maquet Cardiovascular’s patent rights in heart-pump technology.
The jury determined that Abiomed’s Impella intravascular heart pumps used to treat heart failure did not infringe a patent related to competing pumps made by Maquet, an Abiomed attorney told Reuters on Friday. The jury also found the patent invalid.
Maquet is owned by Sweden-based Getinge Group (ST:GETIb). Representatives for the company did not immediately respond to requests for comment on the verdict on Friday.
A J&J spokesperson said on Friday that the verdict "vindicates what we have maintained all along: Abiomed invented a life-saving heart pump and Maquet’s patent cannot be stretched so far as to capture Abiomed’s innovation."
Abiomed’s first Impella models received U.S. Food and Drug Administration approval in 2008. Johnson & Johnson completed a $16.6 billion all-cash deal in 2022 to acquire Abiomed to boost growth in its medical devices unit.
Abiomed products including its flagship Impella pumps generated $1.75 billion in worldwide revenue for J&J in 2025. The FDA has issued several recalls related to Impella models in recent years.
The verdict stems from a lawsuit Maquet filed in 2017, accusing Massachusetts-based Abiomed’s Impella pumps of infringing a patent covering a design for a heart pump that can be placed in a specific location within a patient’s circulatory system.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.